Checking for leftover tumor after liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial uses a special scan to measure iodine deposited in the liver after a standard treatment called chemoembolization. The goal is to see if the scan can spot tiny bits of tumor that might have been missed, helping doctors decide if more treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC)
- You are able to swallow tablets
- You do not have diabetes that requires insulin injections
- You do not have a thyroid condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.
This trial tests if a shorter MRI scan can effectively monitor liver cancer after a procedure called TACE. If you've had TACE for liver cancer and have good liver function, you may be able to join.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This trial uses CT scans to measure the volume of liver tumors in people with hepatocellular carcinoma (HCC) who cannot have surgery. The goal is to see if this measurement helps guide treatment with TACE, a procedure that blocks blood flow to the tumor.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.